Sopharma announces sale of treasury shares on Bulgarian Stock Exchange

Vesela Lyubenova Stoeva Deputy Chairman of the Board of Directors Sopharma AD
Vesela Lyubenova Stoeva Deputy Chairman of the Board of Directors - Sopharma AD
0Comments

Sofia, Bulgaria – On June 27, 2025, “Sopharma” AD (listed as SFA on the Bulgarian Stock Exchange and SPH on the Warsaw Stock Exchange) executed a sale of 6,000 repurchased own shares. This transaction represented 0.003% of the company’s share capital and was conducted at a total value of BGN 39,760.00 on the Bulgarian Stock Exchange. The average price per share during this transaction was BGN 6.63.

Following this sale, the total number of treasury shares held by “Sopharma” AD stands at 9,414,082, which accounts for 5.24% of the company’s share capital.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.